We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
Read MoreHide Full Article
Key Takeaways
CYTK entered the commercial stage after FDA approval of Myqorzo for symptomatic oHCM.
CYTK reported early Myqorzo traction with 275 prescribers and about 680 patients by Q1-end.
Aficamten advanced with positive ACACIA-HCM data and an FDA-reviewed oHCM label expansion.
Shares of Cytokinetics, Incorporated (CYTK - Free Report) have gained 18.4% year to date against the industry’s decline of 1.3%.
The company has entered a pivotal phase following the FDA approval of its first commercial product, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Image Source: Zacks Investment Research
The approval marks the company’s transition into a commercial-stage biotech.
The impressive year-to-date performance can be attributed to strong first-quarter results supported by early Myqorzo launch.
Strong Initial Myqorzo Uptake Boosts CYTK
Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. It is approved in the United States and China for the treatment of adults with symptomatic oHCM.
Myqorzo works by inhibiting cardiac myosin, thereby reducing excessive cardiac contractility and alleviating left ventricular outflow tract obstruction in patients with oHCM.
The company initiated the U.S. commercial rollout in January 2026. Early launch metrics indicate strong physician engagement and patient uptake, with over 275 unique healthcare providers prescribing the drug and approximately 680 patients being prescribed Myqorzo by the end of the first quarter.
More than 70% of patients on therapy transitioned to paid prescriptions.
The European Commission approval in February 2026 further expands Myqorzo's addressable market and provides an additional growth catalyst.
Cytokinetics recently achieved an important commercial milestone with the first European launch of Myqorzo in Germany, marking the drug's entry into the EU market.
CYTK is also working on a label expansion of Myqorzo. The FDA accepted its supplemental new drug application for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Meanwhile, aficamten continues to be evaluated across additional patient populations, supporting potential lifecycle expansion opportunities. The drug was studied in the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy (nHCM).
The ACACIA-HCM study successfully met both co-primary endpoints, demonstrating statistically significant improvements from baseline through week 36 in both Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and maximal exercise performance (peak VO2). Statistically significant improvements compared to placebo were also observed in key secondary endpoints.
It is currently being investigated in the CEDAR-HCM study in pediatric patients with oHCM. Aficamten is also being evaluated in the ongoing FOREST-HCM open-label extension study.
CYTK’s Encouraging Pipeline Progress
Other pipeline candidates include omecamtiv mecarbil, a cardiac myosin activator. A confirmatory phase III study, COMET-HF, is ongoing in patients with symptomatic heart failure with severely reduced ejection fraction. Enrollment is expected to continue through the rest of 2026.
Following a recommendation from the dose level review committee, patient enrollment has been expanded in Cohort 1 of AMBER-HFpEF, a phase II study evaluating ulacamten in symptomatic heart failure with preserved ejection fraction (HFpEF) patients with left ventricular ejection fraction (LVEF) ≥ 60%. Enrollment in Cohort 1 is expected to be completed in the second half of 2026.
Road Ahead for CYTK
The approval of Myqorzo is a significant boost for CYTK, given the oHCM market potential. However, investors should remain mindful of risks, including launch execution and competition.
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) .
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III oHCM to improve functional capacity and symptoms.
Earlier this month, the FDA accepted BMY’s supplemental new drug application (sNDA) seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM. The FDA granted Priority Review to the application with a target action date of Sept. 30, 2026.
If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescents with oHCM and expand the drug's addressable market beyond adults.
While Myqorzo represents a meaningful growth driver and a validation of Cytokinetics’ muscle biology platform, sustained commercial traction will be critical to supporting long-term valuation upside.
Over the past 30 days, earnings per share (EPS) estimates for Immunocore have remained unchanged at 6 cents for 2026 and at 87 cents for 2027.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 97.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
Key Takeaways
Shares of Cytokinetics, Incorporated (CYTK - Free Report) have gained 18.4% year to date against the industry’s decline of 1.3%.
The company has entered a pivotal phase following the FDA approval of its first commercial product, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Image Source: Zacks Investment Research
The approval marks the company’s transition into a commercial-stage biotech.
The impressive year-to-date performance can be attributed to strong first-quarter results supported by early Myqorzo launch.
Strong Initial Myqorzo Uptake Boosts CYTK
Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. It is approved in the United States and China for the treatment of adults with symptomatic oHCM.
Myqorzo works by inhibiting cardiac myosin, thereby reducing excessive cardiac contractility and alleviating left ventricular outflow tract obstruction in patients with oHCM.
The company initiated the U.S. commercial rollout in January 2026. Early launch metrics indicate strong physician engagement and patient uptake, with over 275 unique healthcare providers prescribing the drug and approximately 680 patients being prescribed Myqorzo by the end of the first quarter.
More than 70% of patients on therapy transitioned to paid prescriptions.
The European Commission approval in February 2026 further expands Myqorzo's addressable market and provides an additional growth catalyst.
Cytokinetics recently achieved an important commercial milestone with the first European launch of Myqorzo in Germany, marking the drug's entry into the EU market.
CYTK is also working on a label expansion of Myqorzo. The FDA accepted its supplemental new drug application for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.
Meanwhile, aficamten continues to be evaluated across additional patient populations, supporting potential lifecycle expansion opportunities. The drug was studied in the phase III ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy (nHCM).
The ACACIA-HCM study successfully met both co-primary endpoints, demonstrating statistically significant improvements from baseline through week 36 in both Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and maximal exercise performance (peak VO2). Statistically significant improvements compared to placebo were also observed in key secondary endpoints.
It is currently being investigated in the CEDAR-HCM study in pediatric patients with oHCM. Aficamten is also being evaluated in the ongoing FOREST-HCM open-label extension study.
CYTK’s Encouraging Pipeline Progress
Other pipeline candidates include omecamtiv mecarbil, a cardiac myosin activator. A confirmatory phase III study, COMET-HF, is ongoing in patients with symptomatic heart failure with severely reduced ejection fraction. Enrollment is expected to continue through the rest of 2026.
Following a recommendation from the dose level review committee, patient enrollment has been expanded in Cohort 1 of AMBER-HFpEF, a phase II study evaluating ulacamten in symptomatic heart failure with preserved ejection fraction (HFpEF) patients with left ventricular ejection fraction (LVEF) ≥ 60%. Enrollment in Cohort 1 is expected to be completed in the second half of 2026.
Road Ahead for CYTK
The approval of Myqorzo is a significant boost for CYTK, given the oHCM market potential. However, investors should remain mindful of risks, including launch execution and competition.
Myqorzo operates within an evolving treatment landscape for oHCM. Its primary competitor is Camzyos, a cardiac myosin inhibitor marketed by Bristol Myers Squibb (BMY - Free Report) .
BMY obtained FDA approval for Camzyos in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III oHCM to improve functional capacity and symptoms.
Earlier this month, the FDA accepted BMY’s supplemental new drug application (sNDA) seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM. The FDA granted Priority Review to the application with a target action date of Sept. 30, 2026.
If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescents with oHCM and expand the drug's addressable market beyond adults.
While Myqorzo represents a meaningful growth driver and a validation of Cytokinetics’ muscle biology platform, sustained commercial traction will be critical to supporting long-term valuation upside.
CYTK’s Zacks Rank & Key Picks
Cytokinetics currently carries a Zacks Rank #3 (Hold). A couple of better-ranked biotech stocks are Immunocore (IMCR - Free Report) and Liquidia Corporation (LQDA - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share (EPS) estimates for Immunocore have remained unchanged at 6 cents for 2026 and at 87 cents for 2027.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 97.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.